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INTRODUCTION
Mefenamic acid (MA) is an active pharmaceutical ingredient that has anti-inflammatory and analgesic activities. It is used clinically to relieve mild to moderate pain and in the treatment of rheumatoid arthritis [1] . In addition, MA is also reported to exhibit a neuroprotective effect [2] . This drug is classified into BCS class II, according to the biopharmaceutical classification system which is a drug with low solubility and high permeability [3, 4] . Low drug solubility in water will cause low absorption of drugs in the gastrointestinal fluid. To optimize the absorption and, thus, the bioavailability of MA in the systemic circulation, it is critical to improving its dissolution rate in aqueous medium [5, 6] . Several studies have been carried out to improve the solubility and dissolution rate of MA, including reduction of particle size, formation of solid dispersion, complexes inclusion, self-emulsifying formulation, molecular complexes, nanocrystals formation, the addition of surfactants, spray drying and freeze drying technique [4, [7] [8] [9] [10] [11] [12] [13] [14] .
Solid-state properties of drug compounds significantly influence their physicochemical properties and bioavailability [15, 16] . One of the interesting strategies to change the solid-state properties to improve solubility and dissolution rate is the formation of a multicomponent phase by crystal engineering techniques [17] . Multicomponent crystals of pharmaceutical materials consist of co-crystal, salt, hydrate and solvate. Modification of physicochemical properties of an active pharmaceutical ingredient (API) via crystal engineering has become a popular approach because this approach can improve solubility, dissolution rate, compressibility, physical and chemical stability and pharmacological effectiveness [18] [19] [20] [21] [22] .
Our previous finding has shown that MA can form salt type multicomponent crystal with N-Methyl-D-Glucamine with improved the dissolution rate and physical stability [22] . In the current study, we prepared multicomponent crystals of MA ( Fig. 1A) with tromethamine (TM) ( Fig. 1B) by the solvent evaporation technique. TM is a GRAS (generally recognized as safe) excipient according to FDA (the US Food and Drug Administration) and is widely used as an alkalizer and biological buffer. Moreover, TM is also used as a salt co-former for some weak acid drugs to improve the physicochemical properties [23, 24] . To our knowledge, 
RESULTS AND DISCUSSION
The initial evaluation of the multicomponent crystal phase is the crystal habit using an SEM microscope apparatus. The crystallization process of the API from various solvents can produce different crystal habit, polymorphs and particle sizes. Crystal habit is one of the essential physicochemical properties in the manufacturing process. The crystal habit will affect the flowability, compressibility, dissolution rate and bulk density of the API particles [25, 26] . In most cases, the solid-state interaction of the binary system API with excipients often produces a new crystal habit that is different from its forming compounds [27, 28] . PXRD analysis is a reliable technique for determining the degree of crystallinity and the formation of new crystalline phases. Each solid crystalline phase has a distinctive diffraction pattern which can be used as a fingerprint for each crystalline phase [29] . The PXRD patterns of MA, TM and multicomponent crystals MA-TM are presented in Fig. 3 . MA is a crystalline solid with sharp diffraction peaks at 2 = 13.84, 15.03, 15.65, 20.02, 21.21, 26.03, 27.67, 31.24 and 31.87. The MA diffractogram shows the polymorph I as reported by a previous study [30] . TM also has a high degree of crystallinity, with typical diffraction peaks at 2 = 14.01, 18.09, 20.13, 22.40, 25.06, 26.76 and 33.79. On the other hand, the diffractogram of the physical mixture of MA-TM is only a superimposition of the interference peaks of MA and TM. Furthermore, the diffractogram of MC shows a distinct pattern which is different from intact MA and TM. Some new diffraction peaks appear at 2 = 11.85, 17.52, 19.56, 21.60, 23.42 and 29.37. This result proves that a multicomponent crystal phase is formed between MA and TM in the equimolar ratio (1:1). The multicomponent crystals include cocrystals, salt, solvate and hydrate. The pKa rule can be one of the guidelines for predicting whether the interactions between the two solid phases (active pharmaceutical ingredients and excipients) form either a cocrystalline phase or salt. The cocrystalline phase is likely to be formed if the pKa difference between the API and the excipient <2. Whereas, if the pKa difference >3, then it can form a salt-type multicomponent crystal [31, 32] . The pKas of MA and TM are reported as 4.2 and 8.07, respectively [11, 33] . In the present study, the difference in pKa between these two solid phases is 3.87 (>3). Based on the ΔpKa rule it can be assumed that the interaction between MA and TM is through the formation of salt-type multicomponent crystals. The DSC thermal analysis was applied to characterize the solid-phase thermodynamic properties. Thermal analysis is also used to screen for the multicomponent crystal phase formation [34] . Herein, MA shows a sharp endothermic peak at 232.8 °C, which is the melting point of MA. Meanwhile, TM shows two endothermic peaks, at 137.1 °C and 170.5 °C (Fig. 4) . The endothermic peak at 170.5 °C, is the melting point of TM, whereas at 137.1 °C is a temperature of a solid-state transition [24] . The multicomponent crystal shows a single endothermic peak (110 °C) which is different from the two constituent components. The melting point of the multicomponent crystal of MA-TM was lower than intact MA. The melting point of the molecular crystal of active pharmaceutical ingredients is correlated with the lattice energy of its crystalline phase. In general, the lower the melting point of a solid phase, the lower the lattice energy. The low lattice energy of a crystalline phase would allow it to dissolve faster in aqueous medium [35, 36] .
FT-IR spectroscopy analysis is widely used to evaluate the solid-state interaction within multicomponent crystal systems. The changes and shifts of absorption bands in the FT-IR spectra indicate an inter-intramolecular bonding and interaction between drug and co-former in the crystal lattice [37] . FT-IR spectra of MA and MA-TM are presented in Fig. 5 . MA demonstrates some characteristic absorption peaks for at wavenumbers 3306.45 cm -1 (-NH), 2859.20 cm -1 (-CH3), 1643.81 and 1576.66 cm -1 (-COOH), and 1436.90, 1243.77, and 1160.69 cm -1 (symmetric deformation vibrations of -CH3 group) [38] . Interestingly, the spectrum shows that the stretching vibration of the carbonyl group of COOH previously seen in MA at 1643.81 cm -1 is shifted to a lower wavenumber in the multicomponent crystal (1558 cm -1 ). This change shows a stretching vibration of the carboxylate anion (COO -). Therefore, according to the data, it is assumed that solid-state interactions of MA-TM might involve proton transfer from MA molecules to TM molecules. This phenomenon is very reasonable because the pKa difference between MA and TM is quite significant (3.87) [11, 32] . In general, there are two approaches to enhance the solubility and dissolution rate of poorly soluble drugs: 1) physicochemical properties modification of solid drug substances, and 2) manufacturing process and formulation strategies [39] . The formation of multicomponent crystals of MA-TM is an interesting approach to improving the dissolution rate of MA, which is a poorly soluble drug. Dissolution rate and bioavailability of the solid dosage form of MA are influenced by solid-state properties such as polymorphic properties, hydrophobicity and its particle size [40, 41] . In addition, MA undergoes a phase transition due to mechanical stress and high relative humidity. This causes a transformation of form II of MA to form I which is less soluble [42, 43] . In the current study, we report the formation of a new salt-type multicomponent crystal of MA-TM with an increased dissolution rate and dissolution efficiency. The dissolution rates of MA-TM and intact MA are demonstrated in Fig. 6 , while the dissolution efficiency is presented in Table 1 . The dissolution efficiency of salt-type multicomponent crystal MA-TM was 2.5-fold higher than intact MA. Furthermore, the dissolution efficiency was also significantly enhanced. The salt formation is proven to improve the physicochemical properties of APIs, especially the solubility and dissolution rate. Previous studies have reported an increase in solubility and dissolution rate of MA via multicomponent crystal phase with some excipients such as nicotinamide, cytosine, pyridine derivative [44] [45] [46] . Average data are presented as mean ± standard deviation, statistical analysis was conducted by independent t-test (95% confidence interval). There are several factors that might contribute to increasing the dissolution rate of a multicomponent crystal of MA-TM. First, salt type multicomponent crystal of MA-TM has a better affinity for the aqueous medium because the solid phase is more hydrophilic. When in contact with the aqueous medium, the salt form will dissociate into cationic and anionic ions. Second, from a solid-state properties point of view, there were changes in the crystal structure and the melting point of the crystalline phase. The melting point of a crystalline solid is influenced by the lattice energy, which binds molecules in the unit cell. The lower the melting point of the solid phase, the weaker the lattice energy of the crystalline phase. Hence, the dissolution rate is faster [18, 24, 33, 36] . 
CONCLUSION
A new salt-type multicomponent crystal of mefenamic acid-tromethamine is successfully prepared using the solvent co-evaporation technique. This multicomponent crystal shows remarkable changes in thermodynamic and crystallographic properties. Notably, the dissolution rate and dissolution efficiency of the salt-type multicomponent crystals of mefenamic acid-tromethamine are significantly higher than intact mefenamic acid.
